Augurex Life Sciences Corp.

Augurex Life Sciences Corp. Augurex is a clinical diagnostics leader advancing biomarker-driven solutions for the early detection and management of autoimmune diseases.

Augurex is a clinical diagnostics leader advancing biomarker-based tests for autoimmune diseases, enabling earlier, more precise detection and disease management to improve patient outcomes. Our lead products include JOINTstat® (14-3-3eta), which supports the diagnosis and monitoring of rheumatoid arthritis (RA), and SPINEstat™ (Anti-14-3-3eta Multiplex), a first-in-class blood test that aids in the diagnosis of axial spondyloarthritis (axSpA) and helps distinguish it from mechanical back pain. By enabling earlier, more precise diagnosis and better disease management, we empower clinicians and patients with the tools to take control of disease and improve long-term outcomes.

We’re pleased to share that the 14-3-3eta test for rheumatoid arthritis (RA) will launch through Sonic Reference Laborat...
11/17/2025

We’re pleased to share that the 14-3-3eta test for rheumatoid arthritis (RA) will launch through Sonic Reference Laboratory in the United States on December 15, 2025.

This launch expands access to a blood test that enables earlier RA diagnostic and prognostic insights and more precise ongoing monitoring, giving patients and their healthcare providers a clearer view of disease progression and treatment response.

With Sonic Healthcare USA’s national reach and commitment to diagnostic excellence, this agreement represents another important step in Augurex’s deepening commitment in making advanced RA testing broadly accessible and improving outcomes for patients across the U.S. and around the world.

Read more in our press release: https://augurex.com/augurex-life-sciences-corp-announces-the-launch-of-the-14-3-3eta-test-for-rheumatoid-arthritis-diagnosis-and-monitoring-with-sonic-reference-laboratory/

November 2–8 is National Pain Awareness Week, a time to recognize the millions of people living with chronic pain from c...
11/02/2025

November 2–8 is National Pain Awareness Week, a time to recognize the millions of people living with chronic pain from conditions like rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA).

At Augurex, we stand with patients and clinicians working toward earlier diagnosis and better management of inflammation-driven pain. Through innovative biomarker-based diagnostics such as JOINTstat® for RA and SPINEstat® for axSpA, we help enable earlier detection of disease activity to support timely treatment decisions before pain leads to lasting joint or spinal damage.

Together, we can raise awareness, improve understanding, and help drive earlier, more targeted care for those affected by chronic inflammatory pain.

We’re excited to see RheumNow highlight Dr. Atul Deodhar’s perspective on biomarker discovery in axial spondyloarthritis...
10/31/2025

We’re excited to see RheumNow highlight Dr. Atul Deodhar’s perspective on biomarker discovery in axial spondyloarthritis (axSpA) in their coverage from ACR Convergence 2025 in Chicago.

In this segment, Dr. Deodhar reviews Augurex’s new data presentations (one oral and two posters), which showcased promising data on the Anti-14-3-3eta Multiplex Immunoassay Test improving early detection and aiding in more accurate clinical decision-making in patients with axSpA. In particular, the data highlighted the Anti-14-3-3eta Multiplex Test complementing HLA-B27 and CRP, helping physicians better differentiate axSpA from mechanical back pain to support earlier, more confident diagnosis.

🎥 Watch RheumNow’s full coverage here: https://www.youtube.com/watch?v=X8Sc_3oBSVA

RheumNow’s on-the-ground coverage at the ACR 2025 conference featured Augurex’s new data on the Anti-14-3-3eta Multiplex...
10/28/2025

RheumNow’s on-the-ground coverage at the ACR 2025 conference featured Augurex’s new data on the Anti-14-3-3eta Multiplex Immunoassay Test in axSpA and mechanical back pain patients.

In the segment, Dr. Akhil Sood highlights that “the biomarker can distinguish who has axSpA and who does not, and this is a promising step toward a simple diagnostic tool.”

This recognition underscores the growing clinical relevance of SPINEstat® (Anti-14-3-3eta Multiplex Immunoassay Test) in supporting earlier and more accurate clinical decision-making in axial spondyloarthritis (axSpA).

🎥 Watch the RheumNow coverage here: https://www.youtube.com/watch?v=EvKv45qybDo

We are pleased to share that the U.S. FDA has granted Breakthrough Device Designation for SPINEstat® (14-3-3eta Autoanti...
10/28/2025

We are pleased to share that the U.S. FDA has granted Breakthrough Device Designation for SPINEstat® (14-3-3eta Autoantibody Multiplex Immunoassay Test) - Augurex’s first-in-class blood test to aid in the diagnosis of patients with axial spondyloarthritis (axSpA).

Breakthrough designation recognizes the significant unmet need in early and accurate axSpA diagnosis, where patients often face long delays before receiving appropriate care.

SPINEstat® detects autoantibodies to the 14-3-3eta protein. In combination with clinical findings, signs and symptoms, SPINEstat® may aid in the differentiation of patients with axSpA from those with mechanical back pain, to support earlier, more confident clinical decision making and diagnosis.

🔗 Read the full press release on our website: https://augurex.com/augurex-life-sciences-granted-fda-breakthrough-designation-for-spinestat-its-first-in-class-diagnostic-test-for-axial-spondyloarthritis/

Patient advocacy is vital in improving awareness, education, and care for those living with rheumatoid arthritis.We’re p...
10/22/2025

Patient advocacy is vital in improving awareness, education, and care for those living with rheumatoid arthritis.

We’re proud to partner with AiArthritis as they spotlight the importance of 14-3-3eta testing through their new patient education blog and updated RA diagnosis page, giving patients trusted information that empowers them to play an active role in their care.

This patient-focused resource highlights how the 14-3-3eta blood test can:
✅ Detect RA earlier, even in patients who test negative for RF and anti-CCP
✅ Identify patients at higher risk of joint damage
✅ Track response to treatment and support remission planning

In addition, AiArthritis has updated their RA diagnosis page to include 14-3-3eta, providing patients with even more resources on how this marker can support diagnosis and ongoing care.

👉 Read their blog here: https://www.aiarthritis.org/decoding-biomarkers
👉 Visit the updated RA diagnosis page: https://www.aiarthritis.org/rheumatoidarthritis

Augurex will exhibit and present new data on the Anti-14-3-3eta Multiplex assay in axial spondyloarthritis (axSpA) at AC...
10/17/2025

Augurex will exhibit and present new data on the Anti-14-3-3eta Multiplex assay in axial spondyloarthritis (axSpA) at ACR Convergence 2025 in Chicago, Illinois, October 24–29.

Visit us at Booth 919 and join us for our latest research, featuring one oral presentation and two posters that highlight the diagnostic value of 14-3-3eta autoantibodies (Anti-14-3-3eta Multiplex) to enable earlier and more accurate detection of axSpA:

Oral Presentation
- Autoantibodies to 14-3-3eta: A Novel Diagnostic Biomarker for Axial Spondyloarthritis
📅 Tuesday, Oct 28 | 🕒 3:45–4:00 p.m. CT | Room W183A-C
👨‍⚕️ Presenter: Raj Sengupta

Poster Presentations
- Evaluating the Diagnostic Utility of 14-3-3eta Autoantibodies in Axial Spondyloarthritis: A Multiplex Assay Approach
📅 Sunday, Oct 26 | 🕒 10:30 a.m.–12:30 p.m. CT | Poster Hall F1

- The 14-3-3eta AAb biomarker improves discriminative performance of CRP and HLA-B27 to differentiate people with radiographic axSpA from those with mechanical back pain
📅 Tuesday, Oct 28 | 🕒 10:30 a.m.–12:30 p.m. CT | Poster Hall F1

We look forward to connecting with rheumatology experts, clinicians, and researchers driving innovation in diagnostics to improve patient outcomes. To schedule a meeting during the conference, please reach out to Neil Klompas, Simran Chahal, Anthony Marotta, PhD, or Nima Mazinani, PhD.

🔗 Learn more: https://augurex.com/augurex-to-exhibit-and-present-new-data-on-anti-14-3-3eta-multiplex-in-axial-spondyloarthritis-at-acr-convergence-2025/

We’re excited to announce our new agreement with , a leading Canadian rheumatology specialty laboratory.JOINTstat® (14-3...
10/15/2025

We’re excited to announce our new agreement with , a leading Canadian rheumatology specialty laboratory.

JOINTstat® (14-3-3eta) testing will be available through MitogenDx starting January 1, 2026 — expanding access to advanced rheumatoid arthritis (RA) diagnostics across Canada.

This represents an important step towards expanding access to innovative biomarker testing to support earlier and more accurate diagnosis and disease monitoring for people living with RA.

Together, Augurex and MitogenDx are advancing the reach of precision diagnostics to help clinicians make more informed treatment decisions and improve outcomes for people living with rheumatoid arthritis.

🔗 Learn more: https://augurex.com/augurex-announces-expansion-of-availability-of-the-jointstat-diagnostic-test-for-rheumatoid-arthritis-with-mitogendx

We’re excited to announce that Augurex will be presenting important new data on the Anti-14-3-3eta Multiplex assay in ax...
09/24/2025

We’re excited to announce that Augurex will be presenting important new data on the Anti-14-3-3eta Multiplex assay in axial spondyloarthritis (axSpA) at the upcoming American College of Rheumatology (ACR) Convergence 2025 in Chicago.

Highlights include an oral presentation by Prof. Raj Sengupta and poster presentations from Dr. Walter Maksymowych and Dr. Anthony Marotta focused on the diagnostic utility of 14-3-3eta autoantibodies in differentiating axSpA from mechanical back pain.

With diagnostic delays continuing to impact patient outcomes, these findings underscore the importance of innovative biomarkers like SPINEstat® (Anti-14-3-3eta Multiplex) in helping clinicians provide earlier and more accurate care.

📅 October 24–29, 2025 | Chicago, IL

Learn more: https://augurex.com/augurex-announces-upcoming-oral-and-poster-presentations-at-the-american-college-of-rheumatology-convergence-2025

September is Chronic Pain Awareness Month. For 1 in 5 people in the US and Canada, pain is not temporary. It follows the...
09/17/2025

September is Chronic Pain Awareness Month. For 1 in 5 people in the US and Canada, pain is not temporary. It follows them to work, interrupts sleep, and affects emotional health.

Rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA) are two conditions where pain can be intense and unrelenting. Yet with earlier diagnosis and treatment, lives can change.

At Augurex, we focus on giving patients and physicians answers sooner through biomarker-based testing. Tools like JOINTstat® and SPINEstat® help detect disease earlier and support treatment decisions that ease the burden of pain.

This month, we stand alongside those living with chronic pain and reaffirm our commitment to advancing solutions that improve quality of life.

September is Arthritis Awareness Month. More than six million Canadians live with arthritis, making it one of the most c...
09/15/2025

September is Arthritis Awareness Month. More than six million Canadians live with arthritis, making it one of the most common chronic diseases in the country.

Too often arthritis is seen as minor stiffness or aches. In reality, conditions like rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA) can lead to irreversible joint damage when left untreated. The earlier the diagnosis, the greater the chance to protect mobility and independence.

Augurex is working with healthcare providers, patients, and advocacy partners to change the story. Our advanced biomarker tests, JOINTstat® and SPINEstat®, are designed to shorten the time to diagnosis and support timely intervention.

This September, we invite you to join us in raising awareness and supporting innovations that create better outcomes for people living with arthritis.

Augurex is exhibiting and presenting new data at the Congress of Clinical Rheumatology West (CCR West) 2025 in Huntingto...
09/08/2025

Augurex is exhibiting and presenting new data at the Congress of Clinical Rheumatology West (CCR West) 2025 in Huntington Beach, California from September 18–21.

This annual conference brings together rheumatologists and researchers to share the latest insights in autoimmune and inflammatory disease care.

Join us at Booth #48 and don’t miss our poster presentations:

High Specificity and Diagnostic Utility of Serum 14-3-3η in Rheumatoid Arthritis: Evidence from a Clinically Diverse Cohort

Validation of a 14-3-3η Autoantibody Assay Combined with CRP and HLA-B27 to Improve Axial Spondyloarthritis Detection

- Presenting Author: Anthony Marotta, PhD
- Friday, September 19 | 3:10 PM

If you are attending CCR West, connect with Marotta, PhD and Chahal to learn more about how Augurex’s innovative biomarkers, 14-3-3eta for RA and the Anti-14-3-3eta Multiplex for axSpA, are supporting earlier diagnosis and better outcomes.

Learn more: https://augurex.com/augurex-to-exhibit-and-present-new-data-at-ccr-west-2025

Address

887 Great Northern Way, Suite 220
Vancouver, BC
V5T4T5

Telephone

+16046373280

Website

Alerts

Be the first to know and let us send you an email when Augurex Life Sciences Corp. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Augurex Life Sciences Corp.:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Augurex is a biotech company that is focused on developing biomarker blood tests that transform patient clinical management for better disease outcomes.